Good candidates: Adults with obesity (BMI 30+) who have not responded to diet and exercise alone Adults with overweight (BMI 27+) and a related health condition Patients with type 2 diabetes seeking better blood sugar control alongside weight loss Who should avoid semaglutide: People with a personal or family history of medullary thyroid carcinoma (MTC) People with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Pregnant or breastfeeding women People with a history of pancreatitis (use with caution, discuss with your doctor) Anyone with severe gastrointestinal disease Always disclose your full medical history to your prescribing provider before starting
L-arginine decreases inflammation and modulates the nuclear factor-kappaB/matrix metalloproteinase cascade in mdx muscle fibers
The findings of a large US real-world cohort (n= 18,000) study, published in 2024, show that patients on tirzepatide were significantly more likely to achieve 5 %, 10 % and 15 % weight loss compared with semaglutide (HR 1.76, 2.54, 3.24, respectively), with a 12-month mean weight difference of -6.9% 8
Research backs eating it before meals as a practical strategy for reducing overall calorie intake, which is the actual mechanism of fat loss
